MedTrace Logo

Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)

NCT02709616 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-05-27

No results posted yet for this study

Summary

Dendritic cell-based cellular vaccine for tumor therapy has shown efficacy. This study is designed to perform a personalized clinical trial by first analyzing the expression of tumor associated antigens in patients with newly diagnosed glioblastoma and then immunizing the patients with personalized DC-based cellular vaccine. Immune responses to tumor antigens will be monitored. Safety and efficacy will be observed in the study.

Conditions

Interventions

BIOLOGICAL

Personalized cellular vaccine

Biological: DC-based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive biweekly cellular vaccines.

Sponsors & Collaborators

  • Jinan University Guangzhou

    collaborator OTHER

  • Beijing Tricision Biotherapeutics Inc

    collaborator INDUSTRY

  • Zhuhai Trinomab Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Guangdong 999 Brain Hospital

    lead OTHER

Principal Investigators

  • Jian Zhang, M.D. · Guangdong 999 Brain Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-01
Primary Completion
2017-10-31
Completion
2019-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02709616 on ClinicalTrials.gov